The kinin receptor B 1 and the transient receptor potential ankyrin 1 (TRPA1) work as initiators and gatekeepers of nociception and inflammation. This study reports that the nociceptive transmission induced by activation of B 1 receptor is dependent on TRPA1 ion channel. The mechanical hyperalgesia was induced by intrathecal (i.t.) injection of B 1 agonist des-Arginine 9 -bradykinin (DABK) or TRPA1 agonist cin- 
Introduction
The transient receptor potential ankyrin 1 (TRPA1) is a calciumpermeable non-selective ion channel that works as a mechanical, chemical and thermal sensor [1] [2] [3] . TRPA1 is highly expressed in unmyelinated and thinly myelinated sensory neurons [4] [5] [6] . The TRPA1 channel is sensitive to several endogenous and exogenous inflammatory agents. This makes the channel an important trigger of neuron hypersensitivity in inflammatory conditions [3, 6, 7] . In addition to its broad sensitivity, the expression of TRPA1 is up regulated in the dorsal root ganglia after peripheral inflammation [8] [9] [10] . TRPA1 is modulated by GPCRs through second-messenger signaling cascades. The activation of the pruritogen receptors Masrelated GPCR (Mrgprs) A3 and C11 is functionally coupled to TRPA1 via Gbc and PLC [11] and the proteinase-activated receptors (PAR-2 and PAR-4) have their pruritogenic activity associated to the TRPA1 channel opening [12, 13] .
Of relevance, the binding of bradykinin to its GPCR, the B 2 receptor, increases TRPA1-dependent calcium influx in sensory neurons that, in turn, contributes to bradykinin-induced nociception [14, 15] . The stimulation of the kinin receptor B 2 is known to activate PLC, which hydrolyses PIP 2 into diacylglycerol (DAG) and inositol triphosphate (IP 3 ), these pathways are involved in the sensitization of TRPV1 by B 2 receptor [16] [17] [18] . Inositol triphosphate releases calcium from intracellular stores that can modulate TRPA1 opening [14] . Recently, Wang and collaborators showed that, besides PLC, the activation of cyclic adenosine monophosphate/ protein kinase A (cAMP/PKA) in DRG neurons by bradykinin also contributes to sensitize TRPA1 [19] .
Kinins are vasoactive peptides involved in the physiological supply of blood, oxygen and nutrition to tissues [20] . They are increased in plasma and tissues in response to infection, tissue trauma or following acute and chronic inflammatory states. Cell response to kinins occurs through two G protein-coupled receptors, the B 1 and B 2 receptors. The B 2 receptor presents higher affinity for bradykinin and Lys-bradykinin peptides, whereas, the B 1 receptor displays high affinity for the kinin metabolites des-Arg 9 - bradykinin and Lys-des-Arg 9 -bradykinin. B 1 and B 2 receptors have also different constitutive expression, whereas B 2 is widely and constitutively expressed in central and peripheral tissues, B 1 is normally inducible but constitutive in neurons from the central nervous system. The B 1 receptor was identified in the superficial layers of the dorsal horn, confined to the spinal terminals of primary afferent fibres [21] [22] [23] . In spite of its low expression in peripheral tissues, B 1 receptor is highly up regulated in certain inflammatory conditions, for example in response to cytokines and bacterial endotoxins signaling and by a redox imbalance towards an oxidative environment [24] [25] [26] [27] [28] .
Both B 1 receptor and TRPA1 ion channel are constitutively expressed in small diameter afferent fibres in the dorsal horn of the spinal cord and regulate pain transmission [4, 5, 22, 23] . They are also up-regulated in the dorsal horn after peripheral chronic inflammation [8, 9, 29] . Similarly to what occurs for the B 2 receptor, we hypothesized that the activation of B 1 receptor could sensitize TRPA1 channel through intracellular signaling mechanisms. Therefore, we assessed whether the nociceptive transmission triggered by B 1 receptor activation was modulated by TRPA1. The nociceptive response was evaluated after intrathecal injection of the selective B 1 and TRPA1 agonists and antagonists and after silencing TRPA1 expression in spinal cord. The microglia activation after B 1 receptor activation was also evaluated. Finally, we investigated the involvement of the intracellular signaling messenger PKC and PLC in the nociceptive response induced by intrathecal injection of both TRPA1 and B 1 receptor agonists.
Materials and methods

Animals
Experiments were carried out using female adult (2-3 months old) CD1 mice (25-35 g ) from our own breeding colony. The mice were kept in a controlled temperature room (22 ± 1°C) under a 12-h light-dark cycle (lights on at 07:00 h). Food and water were provided ad libitum. Mice (five per cage) were housing in cages with individual ventilation (Ventilife Series, ALESCO, Campinas-SP, Brazil).
Animals were acclimatized to the laboratory for at least 1 h before testing. The experiments were performed with the agreement of the Institutional Ethics Committee (protocol number PP00390) and were carried out in accordance with the current guidelines for the care of laboratory animals and the ethical guidelines for experimental pain investigations in conscious animals [30] . The number of animals and the intensity of noxious stimuli were the minimum necessary to demonstrate a consistent effect of the treatments.
Reagents
The TRPA1 receptor antagonist, HC030031 [2-(1,3- To the intrathecal treatments, the stock solution of HC030031 was mixed to the stock solutions of agonists (cinnamaldehyde or DABK or sterile saline) in a fifty:fifty proportion immediately before the injection. The final concentration of DMSO did not exceed 5% and did not cause any effect per se. AS-ODN was suspended in nuclease-free PBS. A stock solution of indomethacin was dissolved in 5% sodium bicarbonate. Stock solutions of 2 mM U73122 or 2 mM GF 109203X were prepared in ethanol, the final work solutions were diluted in sterile saline and contained 0.3% and 5% ethanol, respectively.
Mechanical hyperalgesia induced by TRPA1 and B1 agonists
The mechanical hyperalgesia was evaluated by measuring the paw withdrawal response in von Frey Hair (VFH, Stoelting, Chicago, IL, USA) application onto the plantar area. For this purpose mice were placed individually in clear Plexiglas boxes (13 Â 18 Â 68 cm), with twelve compartments (9 Â 11 Â 13 cm each), on elevated wire mesh platforms (21 Â 39 Â 74 cm) to allow access to the ventral surface of the right hind paw. The applied mechanical force was in the range of 0.04-2 g, as the up-down method preconized by Chaplan and co-workers [32] . This method allows evaluation of 50% withdrawal threshold and does not achieve a maximum stimulation, decreasing animal discomfort. The graph data represent the average in grams for 50% withdrawal threshold.
The animals were acclimatized into individual boxes for 60 min prior to behavioral testing from 8:00 a.m. Therefore, all behavioral analyses started early in the morning. After this initial adaption, a baseline measurement was taken from all mice. Naïve mice that were excessively responsive to the von Frey Hair were discarded from the experiment. A sham group (PBS, 5 lL via i.t.) was always carried out in parallel to compare any unspecific effect of the intrathecal injection or mice manipulation.
The agonists cinnamaldehyde (1-30 nmol/site) or DABK (0.3-30 nmol/site) were injected by intrathecal route (i.t.) in a volume of 5 lL. The i.t. injections were given to fully conscious mice (n = 6 per group) using a 30-gauge needle attached to a 25 lL micro syringe that was inserted into the subarachnoid space on the midline between the L5 and L6 vertebrae as described previously [33] . After treatment, each mouse was immediately placed back into its respective isolated box. A 30 min of adaption was allowed for the first withdrawal response measurement. Therefore, the measurements were taken at 30 min, 1, 2, 4 and 6 h after the intrathecal treatment. The receptor antagonists HC030031 (1-30 lg/site) and DALBK (50 nmol/site) were co-administered with the agonists always to a final volume of 5 lL. The enzyme inhibitors GF109203X (1 nmol/site), indomethacin (50 lg/site) and U73122 (30 pmol/site) were administered five minutes before ago-nists in a volume of 2.5 lL. The concentration of GF109203X and U73122 was based on previous studies from our group [34] [35] [36] .
In another set of experiments mice were injected with the TRPA1 oligodeoxynucleotide antisense (AS-ODN, sequence 5 0 -TCT ATGCGGTTATGTTGG-3 0 ) or the missense oligodeoxynucleotide (MM-ODN; 5 0 -ACTACTACACTAGACTAC-3 0 ) directed to the specific codifying region of TRPA1. AS-ODN (500 lM) was injected intrathecally in a volume of 5 lL (2.5 nmol/site) as previously established by our group [8, 37] . AS-ODN was administered into the spinal intrathecal space every 12 h, for 3 consecutive days.
The last administration was performed 1 h before the behavioral evaluation. All these behavioral evaluations were performed in a doubleblinded method, i.e., F.C.M. performed the treatments and M.M. carried out the von Frey Hair test.
Immunohistochemical analyses
At the end of the behavioral analyses (6 h after DABK injection) mice were anesthetized with 7% chloral hydrate and transcardially perfused with heparin (1000 U/mL) in 0.9% saline solution, followed by 4% paraformaldehyde in 0.9% saline solution. Chloral hydrate has been a successful anesthetic for transcardial perfusion. The lumbar spinal cord was harvested and post-fixed overnight at room temperature in 4% paraformaldehyde [38] . The immunohistochemistry technique was carried out on paraffin-embedded lumbar (L5-L6) sections. The immunostaining for TRPA1 and Iba-1 was carried out in 4 lm tissue sections using the polyclonal goat anti-TRPA1 antibody 1:2000 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or the monoclonal goat anti-Iba-1 antibody (1:200; Abcam, San Francisco, CA, USA). Following quenching of endogenous peroxidase with 1.5% hydrogen peroxide in methanol for 20 min, high temperature antigen retrieval was performed by immersion of the slides in a water bath at 95-98°C in 10 mM trisodium citrate buffer pH 6.0, for 45 min. After overnight incubation at 4°C with primary antibody, the slides were washed with PBS, incubated with the appropriate biotinylated secondary antibody 1:250 (Dako Cytomation, Carpinteria, CA, USA) for 1 h at room temperature. After that, the sections were washed in PBS and incubated with streptavidin-peroxidase 1:250 (Invitrogen, Carlsbad, CA, USA) for 1 h. The visualization was completed by use of 3,3 0 -diaminobenzidine (DAB) (Dako-Cytomation, Carpinteria, CA, USA) in chromogenic solution and light counterstaining with Harris's hematoxylin solution (Merck KGaA, Darmstadt, Germany). The control and experimental tissues were placed on the same slide and processed under the same conditions. Digital images were acquired by Digital Sight Camera (DS-Fi1, Nikon, Melville, NY, USA) connected to a light microscope (Eclipse 50i, Nikon). Settings for image acquisition were identical for control and experimental tissues. For each mouse spinal cord, four images were obtained. Digitized images were transferred to a computer, and the average pixel intensity of immunostaining was calculated using NIH ImageJ 1.36b imaging software (NIH, Bethesda, MD, USA) and the results were expressed as optical density (O.D.). These experiments were performed in a double-blinded method, F.C.M. performed the treatments, collected and processed the samples and C.P.F performed the immunohistochemical analyses.
Expression of TRPA1 and B 1 mRNA by real time-polymerase chain reaction
The agonist DABK (30 nmol/site) was injected by intrathecal route (i.t.) in a volume of 5 lL. Two or six hours after the treatment lumbar (L5-L6) spinal cord and dorsal root ganglia (DRG) were removed and placed in an RNA holder for the real timepolymerase chain reaction (RT-PCR). The RNA was extracted using TRIzol reagent following the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). The concentration of total RNA was determined by measuring the absorbance at 260 nm. One microgram of the total RNA was reverse transcribed to cDNA using 500 lg/mL oligo(dT), 10 mM dNTP, 100 mM dithiothreitol (DTT), 40 mU/mL RNaseOUT and 200 U of SuperScript reverse transcriptase (Invitrogen, Carlsbad, CA, USA) in a reaction buffer (2.5 mM MgCl 2 , 50 mM KCl, and 20 mM Tris-HCl, pH 8.4), with a final volume of 12.5 lL.
The samples were incubated for 5 min at 65°C, 5 min at 4°C, 50 min at 42°C, 5 min at 70°C, and 5 min at 4°C. The cDNA (100 ng) was amplified in duplicate using TaqMan-based chemistry with specific primers and FAM-labeled probes for mouse TRPA1 (Mm00625268_m1), B 1 (Mm00432059_s1) and GAPDH (Mm01843776_s 1 ) as an endogenous control for normalization (Applied Biosystems, Warrington, UK). Amplifications were carried out in a thermal cycler (StepOne Plus, Applied Biosystems, Warrington, UK) for 50 cycles; the fluorescence was collected for each amplification cycle and the data analyzed using the 2
ÀDDCt method for the relative quantification of expression. Expression of the target genes was calibrated against the conditions found in naive animals, i.e., without any treatment. The DCt mean ± S.D.M. in naïve samples were 17.36 ± 0.44 (TRPA1 in spinal cord) and 11.89 ± 0.02 (TRPA1 in DRG); 13.9 ± 0.25 (B 1 in spinal cord) and 13.98 ± 0.74 (B 1 in DRG).
Statistical analysis
The results are presented as mean ± S.E.M of six animals per group for the behavioral tests and five animals per group for real time-PCR analysis. The data were analyzed by one-way analysis of variance (ANOVA) followed by Duncan's Multiple Range Test or unpaired t test when appropriate. P values less than 0.05 (p < 0.05) were considered to be indicative of significance.
Results
Mechanical hyperalgesia induced by intrathecal injection of TRPA1 agonist
The sensitization of TRPA1 from spinal cord and dorsal root ganglia was performed by the intrathecal injection of cinnamaldehyde. The Fig. 1A shows a dose-response curve for cinnamaldehyde to induce mechanical hypersensitivity. A baseline measurement was performed before the treatments. A sham group (PBS, 5 lL i.t.) was carried out in parallel to compare any unspecific effect of the intrathecal injection or mice manipulation. At the concentration of 10 nmol/site, cinnamaldehyde induced a consistent and well reproducible long-lasting nociception. This concentration was selected for the next experiments. The co-administration of TRPA1 antagonist HC030031 (10 lg/site) significantly prevented the hyperalgesia induced by cinnamaldehyde (Fig. 1B) . The Table 1 shows the threshold for different concentrations of HC030031 assessed two hours after drug administration.
Effect of TRPA1 modulation in the nociceptive transmission induced by B 1 activation in spinal cord
Intrathecal injection of the B 1 receptor agonist DABK induced a concentration-dependent hyperalgesia (Fig. 2A) . The simultaneous treatment with the B 1 receptor antagonist DALBK significantly decreased mechanical hyperalgesia when assessed thirty minutes after treatment. The treatment with the TRPA1 receptor antagonist, HC030031, decreased mechanical hyperalgesia induced by DABK at 1 and 2 h after treatment (Fig. 2B) .
To confirm the involvement of TRPA1 in the nociceptive effect of DABK, we silenced the TRPA1 expression by using TRPA1 antisense. The knockdown of TRPA1 significantly prevented the nociception induced by DABK (Fig. 3A) . The efficiency of the antisense treatment was confirmed by the immunodetection of TRPA1 in the dorsal horn of the spinal cord (Fig. 3B) . The TRPA1 immunostaining was significantly higher in the dorsal horn of DABK treated mice. As expected, the treatment with TRPA1 antisense prevented TRPA1 expression (Fig. 3B). 3.3. TRPA1 and B1 mRNA are over-expressed in lumbar spinal cord and dorsal root ganglia (DRG) after DABK injection By using real time PCR we could detect baseline levels of TRPA1 and B 1 mRNA in lumbar spinal cord and in DRG of naïve mice. Of interest, TRPA1 mRNA was up-regulated in the lumbar spinal cord two hours after DABK injection and returned to the baseline six hours after the treatment (Fig. 4A) . Differently from TRPA1, B 1 mRNA was up-regulated only six hours after DABK injection. The up-regulation of B 1 mRNA was detected in both lumbar spinal cord and DRG (Fig. 4C and D) .
The knockdown of TRPA1 disrupts microglia activation in the spinal cord
The Iba-1 is highly and specifically expressed in monocytic cell lines and cultured microglia [39] . Because of its localization and function, Iba-1 is considered a relevant marker of microglia activation. The administration of DABK induced a significant and diffuse increase in Iba-1 expression in mice spinal cord. Interestingly, the knockdown of TRPA1 channel completely prevented Iba-1 immunostaining increase (Fig. 5) . This result suggests that, beside the hypernociception, TRPA1 also mediates the neuroinflammatory response triggered by B 1 receptor activation.
Inhibition of cyclooxygenase, PKC and PLC decreased the mechanical hyperalgesia induced by TRPA1 and B 1 receptor agonists
Since the down regulation of TRPA1 disrupted the microglia activation induced by DABK, we evaluated the possible contribution of the inflammatory process in the mechanical nociception induced by both TRPA1 and B 1 receptor agonists. As depicted in Fig. 6 , the pre-treatment of animals with indomethacin resulted in a significant decrease in the mechanical hyperalgesia induced by DABK or cinnamaldehyde. In addition, the inhibition of PKC by GF109203X and of PLC by U73122 consistently inhibited the mechanical nociception caused by both agonists, demonstrating that both signaling cascades are involved in the mechanical hypersensitivity induced by the central administration of cinnamaldehyde or DABK. Of note, indomethacin and both GF109203X and U73122 were all effective for up 2 h after treatment (Fig. 6 ).
Discussion
Previous studies demonstrated that the TRPA1 channel is indirectly activated by GPCR, including the Mas-related GPCR A3 and C11, PAR-2 and PAR-4 and the bradykinin receptor B 2 . In this study we extended these previous studies by demonstrating that TRPA1 is secondarily activated by the GPCR B 1 receptor. B 1 is a unique receptor that is constitutively expressed in neurons of the central nervous system but can be quickly up regulated in peripheral tissues in inflammatory conditions [26, 27, 40] . Our main goal was to evaluate B 1 and TRPA1 interaction in nociceptive transmission in the dorsal horn of the spinal cord. The hypothesis for their putative interaction was raised since both receptors are co-expressed in the spinal terminals of primary afferent fibres [4, 5, 22, 23] . To test their effects, it was necessary to standardize the intrathecal doses of the selective agonists that would be necessary to cause mechanical nociception.
A previous report performed a dose-response curve (3-50 nmol/site) to the intrathecal injection of DABK in thermal hyperalgesia. DABK was proved to be highly selective to B 1 receptor in these concentrations because the thermal hyperalgesia was completely abrogated by the selective antagonist DALBK and was absent in B 1 knockout mice [41] . A later study reported no significant thermal nociception in rats that were treated with 9.6 nmol/ site DABK via i.t. In this case, the hyperalgesia was evaluated 1 min after agonist injection [42] . The experiments reported by Ferreira et al. [41] and the data from the present study found a significant thermal or mechanical hyperalgesia 30 min after i.t. injection of DABK. The nociceptive response induced by B 1 receptor agonist is likely dependent on receptor maturation and traffic to plasma membrane [43] We also performed a dose-response curve to evaluate the antinociceptive effect of HC030031 in the mechanical hyperalgesia induced by cinnamaldehyde. The maximum protection against hyperalgesia (84%) was achieved at 10 and 30 lg/site HC030031. From these results, the 30 lg/site concentration was tested against the mechanical hyperalgesia induced by DABK. A previous study from our group revealed that 10 lg/site (i.t.) HC030031 significantly protected from the mechanical hyperalgesia induced by the intraplantar injection of CFA [8] . More recent studies demonstrated a protective effect of the intrathecal injection of HC030031 against mechanical hyperalgesia in neuropathic pain at 10 lg/site [44] and 50 lg/site [45] .
Likewise TRPA1, activation of B 1 receptor is also involved in chronic pain [21, 46] . Chronic pain occurs by a maladaptive neuroplasticity at various levels of the nervous system [47] . In the spinal cord, this neuroplasticity causes a frequency-dependent increase of neuronal excitability (wind-up) [48] . Of note, knockout mice for B 1 receptor presented 50% less wind-up neuroplasticity than wildtype mice after repetitive electrical stimulation of the dorsal root [49] . Therefore, B 1 receptor is an attractive target for treating chronic pain. However, antagonists with a proof-of concept data for clinical use have failed in Phase I or II tests [50] . Thus, antagonists of ion channels or signaling proteins downstream to B 1 receptor would be a reliable alternative for the development of drugs to treat chronic pain.
The pharmacological antagonism or the knockdown of TRPA1 significantly prevented the mechanical hyperalgesia induced by the B 1 receptor agonist, DABK. It has been well established that the activation of many TRP ion channels is linked to G proteincoupled receptors (GPCR) signaling pathways [1] . Experimental evidence showed that TRPA1 and TRPV1 are secondarily activated by the stimulation of B 2 kinin receptor [15] [16] [17] 51] . It is known that the stimulation of either B 1 or B 2 kinin receptors is able to activate PLC that in turn breaks down phosphatidylinositol 4,5-bisphosphate (PIP 2 ) into diacylglycerol (DAG) and inositol triphosphate (IP 3 ). Inositol triphosphate then releases calcium from intracellular stores, while DAG activates protein kinase C (PKC); DAG The mRNA TRPA1 (B) and B 1 (D) from DRG were quantified 6 h after i.t. injection of DABK. The gene transcripts were determined by Taqman qPCR 27 cDNA. Data were normalized by mRNA levels of GAPDH. Expression of the target genes was calibrated against the conditions found in naive animals, i.e., without any treatment. Data represent the mean ± S.E.M. of five mice. Statistical analyses were performed by one-way ANOVA analyses of variance, using Duncan as the post-hoc test in (A) and (C) and unpaired t test in (B) and (D). Symbols denote a statistical difference (*) p < 0.05 from Naïve.
can also be converted into polyunsaturated fatty acids, such as arachidonic acid, by DAG lipase [51] . The signaling molecules that activate TRPA1 downstream of PLC are unknown, but both fatty acid metabolites from diacylglycerol lipase hydrolysis and calcium released from intracellular stores are putative candidates [3, 14, 52, 53] . Another mechanism of TRPA1 activation by GPCR was proposed by Wang and collaborators. These authors showed that the activation of adenylyl cyclase and synthesis of cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) in DRG neurons by bradykinin contributes to sensitizing TRPA1 [19] . A more indirect pathway would involve the activation of phospholipase A 2 (PLA 2 ) and the cyclooxygenases, with production of 15-deoxydelta-12,14-prostaglandin J2 (15d-PGJ2), a potent activator of TRPA1 [3, 52] .
Thus, TRPA1 acts as an integrator molecule and can respond to the release of inflammatory mediators, allowing the amplification of inflammatory and nociceptive processes. Corroborating with the purposed mechanisms, the inhibition of PLC (U73122), PKC (GF109203X) and cyclooxygenase (indomethacin) significantly reduced the mechanical hyperalgesia induced by the TRPA1 agonist cinnamaldehyde and by B 1 selective agonist DABK. The PLC and PKC are well established downstream signaling proteins from GPCRs stimulation [54, 55] . However, the consequence of TRPA1 activation on PLC signaling has been less investigated. In this study, we clearly observed a role of PLC on the mechanical hyperalgesia induced by cinnamaldehyde. This suggests that the calcium influx induced by TRPA1 ion channel could positively modulate PLC activity, since the different isoforms of this enzyme are sensitive to cytosolic calcium [56] . The activation of PLC would then hydrolysis PIP 2 from membrane, similarly to what happens after the GPCRs: PAR2, PAR4, B 1 and B 2 activation. In agreement, the hydrolysis of PIP 2 causes a derepression upon TRPV1 [16, 56] . Although this effect has not been investigated for TRPA1, these two channels present very similar mechanisms of sensitization and desensitization [3] . In addition, PIP 2 has been described to activate TRPA1 [57] . However, further studies are required to elucidate the roles of PLC and PIP 2 in the regulation of TRPA1 channels.
The stimulation of B 1 receptor clearly induced a neuroinflammatory condition. The EF hand protein, Iba-1, was nearly threefold higher in mice treated with DABK when compared to mice that received only vehicle. Iba-1 is a key protein in membrane ruffling and phagocytosis by macrophages and microglia. It colocalizes with filamentous actin (F-actin) in membrane ruffles and it is strongly up regulated in activated microglia [58, 59] . Of relevance, knockdown of TRPA1 significantly prevented microglia activation induced by DABK. Recent studies demonstrated the expression of TRPA1 in monocytes [60] and macrophages [61] . Therefore, a direct cross-talk between TRPA1 and B 1 receptor could be a mechanism for microglia activation. However, no studies have investigated the presence of TRPA1 in microglia so far. Another hypothesis is that a persistent sensitization of TRPA1 in neurons would feed a neuro-inflammatory response and microglia activation. Both mechanisms corroborate with the role of TRPA1 as an integrator and gatekeeper of the inflammatory response [6] . In addition, DABK induced an overexpression of TRPA1 in the dorsal horn of the spinal cord, suggesting that the up regulation of TRPA1 channel is an important mechanism for the mechanical hypersensitivity induced by DABK. In line with these findings, our data show that the oligonucleotide antisense prevented both the up regula- In summary, data from the present study suggest a positive interaction between the TRPA1 ion channel and the kinin B 1 receptor in nociceptive transmission in spinal cord. This conclusion is based on the significant anti-hyperalgesic effect provided by the treatment with the selective antagonist HC030031 and by the down regulation of TRPA1 expression previously to DABK injection. Of note, the administration of the B 1 selective receptor agonist DABK positively modulated TRPA1 and B 1 expression and induced microglia activation. The PKC and PLC revealed to be key pathways in the nociceptive transmission induced by both B 1 and TRPA1 stimulation in spinal cord. Taken together, these findings demonstrated that TRPA1 from the terminal afferents primary in lumbar spinal cord coordinate nociceptive transmission from different stimuli and might be a valuable target to the treatment of pain.
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